



PD Dr. med. Baharak Babouee Flury

Infektiologie | Infektionsprävention | Reisemedizin · Dept. I

Kontakt

PD Dr. med. Baharak Babouee Flury
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 6008
Baharak.BaboueeFlury@kssg.ch

Bereiche

Infektiologie | Infektionsprävention | Reisemedizin

Publikationen (33)

Haller S, Babouee Flury B. Zoonotic poxvirus lesions vs mosquito bite lesions: differential diagnosis of the uncommon vs the common. *J Travel Med* 2023; 30

Bösch A, Macha M, Qun R, Kohler P, Qi W, Babouee Flury B. Resistance development in to delafloxacin at pHs 6.0 and 7.3 compared to ciprofloxacin. *Antimicrob Agents Chemother* 2023; 67:e0162522.

Bilal M, Zoller M, Fuhr U, Jaehde U, Ullah S, Liebchen U, Büsker S, Zander J, Babouee Flury B, Taubert M. Cefepime Population Pharmacokinetics, Antibacterial Target Attainment, and Estimated Probability of Neurotoxicity in Critically Ill Patients. *Antimicrob Agents Chemother* 2023; 67:e0030923.

Kohler P, Babouee Flury B, Güsewell S, Egger T, Leal-Neto O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Ortner M, Rieder P, Ruetti M, Schmid H, Stocker R, Vuichard-Gysin D, Speer O, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Vernazza P, Kahlert C, Kuster S, SURPRISE Study Group. Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study). *Influenza Other Respir Viruses* 2023; 17:e13167.

Babouee Flury B, Bösch A, Gisler V, Egli A, Seiffert S, Nolte O, Findlay J. Multifactorial resistance mechanisms associated with resistance to ceftazidime-avibactam in clinical isolates from Switzerland. *Front Cell Infect Microbiol* 2023; 13:1098944.

Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr P, Darling K, Babouee Flury B, Polli C, Sultan-Beyer L, Abela I, Aebi-Popp K, Swiss HIV Cohort Study (SHCS). Does menopause transition influence viral suppression and adherence in Women living with HIV?. *J Acquir Immune Defic Syndr* 2023

Babouee Flury B, Güsewell S, Egger T, Leal O, Brucher A, Lemmenmeier E, Meier Kleeb D, Möller J, Rieder P, Rütli M, Schmid H, Stocker R, Vuichard-Gysin D, Wiggli B, Besold U, McGeer A, Risch L, Friedl A, Schlegel M, Kuster S, Kahlert C, Kohler P, SURPRISE Study Group. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. *PLoS Med* 2022; 19:e1004125.

Hachfeld A, Abela I, Sultan-Beyer L, Polli C, Babouee Flury B, Darling K, Tarr P, Calmy A, Stute P, Atkinson A, Aebi-Popp K. Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). *HIV medicine* 2022

Seneghini M, Rüfenacht S, Babouee Flury B, Flury D, Schlegel M, Kuster S, Kohler P. It is complicated: Potential short- and long-term impact of coronavirus disease 2019 (COVID-19) on antimicrobial resistance—An expert review. *Antimicrobial Stewardship & Healthcare Epidemiology* 2022

Hachfeld A, Atkinson A, Stute P, Calmy A, Tarr P, Darling K, Babouee Flury B, Polli C, Sultan-Beyer L, Abela I, Aebi-Popp K, Swiss HIV Cohort Study (SHCS). Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). *HIV Med* 2022; 23:417–425.

Seneghini M, Rüfenacht S, Babouee Flury B, Flury D, Schlegel M, Kuster S, Kohler P. It is complicated: Potential short- and long-term impact of coronavirus disease 2019 (COVID-19) on antimicrobial resistance—An expert review. *Antimicrob Steward Healthc Epidemiol* 2022; 2:e27.

Notter J, Seiffert S, Zimmermann-Kogadeeva M, Bösch A, Wenger R, Strahm C, Frischknecht M, Livermore D, Babouee Flury B. AmpC hyperproduction in a <i>Cedecea davisae</i> implant-associated bone infection during treatment: a case report and therapeutic implications. <i>BMC Infect Dis</i> 2022; 22:33.
Leal-Neto O, Kahlert C, Vernazza P, Kuster S, Babouee Flury B, Albrich W, Sumer J, Flury D, Schlegel M, Egger T, Kohler P. Digital SARS-CoV-2 Detection Among Hospital Employees: Participatory Surveillance Study. <i>JMIR Public Health Surveill</i> 2021; 7:e33576.
Barnsteiner S, Kohler P, Kronenberg A, Schlegel M, Plüss-Suard C, Gasser M, Babouee Flury B, Albrich W, Baty F, Swiss Centre for Antibiotic Resistance (ANRESIS). Antimicrobial resistance and antibiotic consumption in intensive care units, Switzerland, 2009 to 2018. <i>Euro Surveill</i> 2021; 26
Kohler P, Egli A, Petignat C, Schlegel M, Münzer T, Harbarth S, Gardiol C, Babouee Flury B, Albrich W, Seth-Smith H, Nolte O, Qalla Widmer L, Lemmenmeier E, Rettenmund G, Kessler S, Seiffert S, Héquet D. Molecular Epidemiology and Risk Factors for Extended-Spectrum β-Lactamase-Producing Enterobacterales in Long-Term Care Residents. <i>J Am Med Dir Assoc</i> 2021
Kahlert C, Albrich W, Babouee Flury B, Besold U, Fehr J, Kuster S, McGeer A, Risch L, Schlegel M, Friedl A, Vernazza P, Wiggli B, Vuichard-Gysin D, Stocker R, Persi R, Güsewell S, Egger T, Leal-Neto O, Sumer J, Flury D, Brucher A, Lemmenmeier E, Möller J, Rieder P, Kohler P. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. <i>Clin Microbiol Infect</i> 2021; 27:1336-1344.
Lorenz L, Silzle T, Brühl D, Haller S, Babouee Flury B (2021). A case of reactive hemophagocytic lymphohistiocytosis - The value of asking the right questions at the right time.
Kohler P, Schlegel M, Risch L, Kuster S, McGeer A, Babouee Flury B, Albrich W, Notter J, Leal-Neto O, Güsewell S, Flury D, Sumer J, Kahlert C, Vernazza P. Prevalence of SARS-CoV-2 antibodies among Swiss hospital workers: Results of a prospective cohort study. <i>Infect Control Hosp Epidemiol</i> 2020; 42:604-608.
Lo Priore E, Livermore D, Buetti N, Jent P, Pelzer N, Casanova C, Furrer H, Babouee Flury B. Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant With Tigecycline Monotherapy. <i>Open Forum Infect Dis</i> 2020; 7:ofz551.
Hebeisen U, Babouee Flury B, Atkinson A, Marschall J, Buetti N. Catheter-related bloodstream infections due to coagulase-negative staphylococci managed with catheter removal: Recurrences are rare. <i>Am J Infect Control</i> 2019; 48:837-839.
Boschung-Pasquier L, Furrer H, Que Y, Jent P, Hauser C, Furrer D, Buetti N, Haschke M, Banholzer S, Kastner L, Atkinson A, Babouee Flury B. Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study. <i>Clin Microbiol Infect</i> 2019; 26:333-339.
Donà V, Scheidegger M, Pires J, Furrer H, Atkinson A, Babouee Flury B. Gradual Evolution of Cefepime Resistance in an ST131 Strain Expressing a Plasmid-Encoded CMY-2 β-Lactamase. <i>Front Microbiol</i> 2019; 10:1311.
Babouee Flury B, Donà V, Buetti N, Furrer H, Endimiani A. First two cases of severe multifocal infections caused by <i>Klebsiella pneumoniae</i> in Switzerland: characterization of an atypical non-K1/K2-serotype strain causing liver abscess and endocarditis. <i>J Glob Antimicrob Resist</i> 2017; 10:165-170.

Babouee Flury B, Ellington M, Hopkins K, Turton J, Doumith M, Woodford N. The differential importance of mutations within AmpD in cephalosporin resistance of *Enterobacter aerogenes* and *Enterobacter cloacae*. *Int J Antimicrob Agents* 2016; 48:555–558.

Babouee Flury B, Frei R, Hinic V, Staves P, Loy R, Doumith M, Turton J, Hopkins K, Ellington M, Woodford N. Association of Novel Nonsynonymous Single Nucleotide Polymorphisms in *ampD* with Cephalosporin Resistance and Phylogenetic Variations in *ampC*, *ampR*, *ompF*, and *ompC* in *Enterobacter cloacae* Isolates That Are Highly Resistant to Carbapenems. *Antimicrob Agents Chemother* 2016; 60:2383–90.

Babouee Flury B, Weisser M, Prince S, Bubendorf L, Battegay M, Frei R, Goldenberger D. Performances of two different panfungal PCRs to detect mould DNA in formalin-fixed paraffin-embedded tissue: what are the limiting factors?. *BMC Infect Dis* 2014; 14:692.

Babouee Flury B, Elzi L, Kolbe M, Frei R, Maja W, Schären S, Widmer A, Battegay M. Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?. *BMC Infect Dis* 2014; 14:226.

Babouee Flury B, Frei R, Battegay M, Savic Prince S, Bubendorf L, Sadowski-Cron C, Lardinois D, Elzi L, Goldenberger D, Weisser M. Prospective study of a panfungal PCR assay followed by sequencing, for the detection of fungal DNA in normally sterile specimens in a clinical setting: a complementary tool in the diagnosis of invasive fungal disease?. *Clin Microbiol Infect* 2013; 19:E354–7.

Elzi L, Babouee Flury B, Vögeli N, Laffer R, Dangel M, Frei R, Battegay M, Widmer A. How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients. *Clin Microbiol Infect* 2012; 18:E355–61.

Babouee Flury B, Elzi L, Frei R, Widmer A, Battegay M. A comment on Marshall et Al. *Clin Infect Dis* 2011; 53:748, author reply 748–9.

Babouee Flury B, Frei R, Battegay M, Führer U, Garzoni C, Betsch B, Droz S, Ciardo D, Dubuis O, Widmer A, Goldenberger D. Emergence of four cases of KPC-2 and KPC-3-carrying *Klebsiella pneumoniae* introduced to Switzerland, 2009–10. *Euro Surveill* 2011; 16

Babouee Flury B, Widmer A, Battegay M. [Vaccination against pneumococci and influenza. How good is the evidence?]. *Internist (Berl)* 2011; 52:265–76.

Babouee Flury B, Frei R, Schultheiss E, Widmer A, Goldenberger D. Comparison of the DiversiLab repetitive element PCR system with *spa* typing and pulsed-field gel electrophoresis for clonal characterization of methicillin-resistant *Staphylococcus aureus*. *J Clin Microbiol* 2011; 49:1549–55.

Projekte (4)

mBiomR; Unravelling the Mechanisms and Dynamics Underlying the Response of Intestinal Bacteria from the ESKAPE group to Antimicrobial Treatment

Grundlagenforschung - 01.03.2023 - 01.03.2027

Laufend

Deciphering the resistance mechanisms of E. coli and P. aeruginosa from UTI and SSI in Tanzania

Grundlagenforschung - 01.11.2021 - 01.11.2024

Laufend

Resistance Development in Escherichia coli at different pH following Delafloxacin and Ciprofloxacin Challenge

Grundlagenforschung - 01.01.2021 - 01.01.2023

Automatisch geschlossen

Multi-omic Approach with Genome editing to unravel the Resistance Mechanisms to Ceftazidime Avibactam in Pseudomonas aeruginosa,

Grundlagenforschung - 20.06.2019 - 01.01.2023

Automatisch geschlossen